Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 3.80 (8.44%)
Spread: 1.00 (2.083%)
Open: 45.00
High: 48.80
Low: 45.60
Prev. Close: 45.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Wed, 14th Jul 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Symphony Environmental Technologies, up 11% at 21.17 pence, 12-month range 10.65p-47.0p. The anti-microbial plastic technologies firm receives approval from the US Food & Drug Administration for its d2p antimicrobial food contact technology.

----------

88 Energy, up 7.9% at 1.89p, 12-month range 0.24p-4.70p. The Alaska-focused oil exploration and appraisal company says additional phase one geochemical analysis of fluid extracts from Merlin-1 well core samples again demonstrates the presence of hydrocarbons. Results from phase two of side-wall core trim analysis are expected in the next few weeks. Phase two is designed to confirm not only the presence of oil but also the nature of the source rock, to help understand the likely quality of the oil as well as migration pathways.

----------

Alpha FX Group, up 6.7% at 1,665.00p, 12-month range 677p-1,720p. The foreign exchange risk management and international payments firm says trading in the first half ended June 30 has been "strong" across its business, with revenue up 89% year on year at GBP34 million. Adds 84 new clients and notes average revenue per client continued to increase. The company expects to exceed current internal expectations for 2021, on the back of continued strong trading. In 2020, saw revenue of GBP46.2 million with pretax profit of GBP17.1 million.

----------

Avacta, up 5.9% at 143.56p, 12-month range 88.66p-291.80p. The developer of diagnostics and cancer therapies says Life Sciences unit gets ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

----------

Fulcrum Utility Services, up 5.6% at 32.74p, 12-month range 28.25p-43.60p. The energy and multi-utility services provider wins new GBP4.9 million multi-utility infrastructure contract from unnamed "large investor developer", for a "major" new employment park in the West Midlands. As part of the contract, the company will design and install a high voltage primary substation and the electricity, water, and gas infrastructure to "energise and power" the new development.

----------

AIM - LOSERS

----------

Tern, down 13% at 19.40p, 12-month range 5.50p-31.67p. The investment firm completes fundraise at the issue price of 18.8p per share. The retail offer and subscription were both oversubscribed and the company said it raised GBP2 million and GBP4 million, respectively. "We intend to utilise the proceeds to maximise the value to our shareholders of our portfolio, and I look forward to providing further updates in due course," says Chief Executive Al Sisto.

----------

Kromek Group, down 7.0% at 15.00p, 12-month range 7.66p-25.20p. The detection technology firm says revenue totalled GBP10.4 million for the financial year that ended April 30 versus GBP13.1 million the year before. Pretax loss, however, narrows to GBP6.3 million from GBP18.3 million loss the year prior. This is due to non-repeat of GBP13.1 million of exceptional impairment losses on trade receivables and amounts recoverable on contracts. Separately, Kromek says it wins new contracts and orders across all segments for delivery this year.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Jun 2023 07:53

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

Read more
5 Jun 2023 12:28

Avacta triggers second milestone payment in AffyXell venture

(Sharecast News) - Life science company Avacta Group announced on Monday that a second milestone equity payment had been triggered, resulting in an increased shareholding for Avacta in AffyXell Therapeutics.

Read more
5 Jun 2023 12:06

Avacta sees shares rise on new equity payment for South Korea venture

(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment.

Read more
1 Jun 2023 14:53

Avacta buys Belgium-based Coris Bioconcept for £7.4m

(Sharecast News) - Life science company Avacta Group announced the acquisition of Coris Bioconcept for initial cash consideration of £7.4m on Thursday.

Read more
1 Jun 2023 10:24

Avacta enhances rapid test portfolio with GBP7.4 million Coris buy

(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio.

Read more
27 Apr 2023 14:34

TRADING UPDATES: Volex wins contract; Engage XR revenue jumps

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2023 12:11

Avacta doses first patient in US tumour treatment trial

(Sharecast News) - Oncology and diagnostics developer Avacta announced the dosing of the first patient in the United States under its investigational new drug (IND) application on Thursday - a milestone for its first therapeutic product 'AVA6000', based on its proprietary 'preCISION' technology.

Read more
25 Apr 2023 14:39

EARNINGS SUMMARY: hVIVO sees 30% revenue growth; Next 15 lifts payout

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
25 Apr 2023 13:51

Revenue rises, adjusted EBITDA loss improves for Avacta

(Sharecast News) - Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.

Read more
18 Apr 2023 15:47

UK earnings, trading statements calendar - next 7 days

Wednesday 19 April 
Antofagasta PLCTrading Statement
discoverIE Group PLCTrading Statement
Distribution Finance Capital Holdings PLCFull Year Results
Hunting PLCTrading Statement
Just Eat Takeaway.com NVTrading Statement
Kainos Group PLCTrading Statement
Liontrust Asset Management PLCTrading Statement
M Winkworth PLCFull Year Results
Network International Holdings PLCTrading Statement
Thursday 20 April 
AJ Bell PLCTrading Statement
Arix Bioscience PLCFull Year Results
Centamin PLCTrading Statement
Deliveroo PLCTrading Statement
Dianomi PLCFull Year Results
Dunelm Group PLCQ3 Results
Foxtons Group PLCTrading Statement
GB Group PLCTrading Statement
Hochschild Mining PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Oxford BioMedica PLCFull Year Results
PensionBee Group PLCTrading Statement
Rentokil Initial PLCTrading Statement
Rio Tinto PLCTrading Statement
Senior PLCTrading Statement
Segro PLCTrading Statement
WH Smith PLCHalf Year Results
Friday 21 April 
Angle PLCFull Year Results
BHP Group LtdTrading Statement
Lookers PLCFull Year Results
Monday 24 April 
Brighton Pier Group PLCFull Year Results
CentralNic Group PLCTrading Statement
Checkit PLCFull Year Results
Egdon Resources PLCHalf Year Results
Keystone Law Group PLCFull Year Results
Lok'n Store Group PLCHalf Year Results
Novacyt SAFull Year Results
Tuesday 25 April 
AB Dynamics PLCHalf Year Results
Anglo American PLCTrading Statement
Associated British Foods PLCHalf Year Results
Avacta Group PLCFull Year Results
Banco Santander SAQ1 Results
Card Factory PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Corero Network Security PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
IWG PLCTrading Statement
Jadestone Energy PLCFull Year Results
Next Fifteen Communications Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Petrofac LtdFull Year Results
Quilter PLCTrading Statement
Resolute Mining LtdTrading Statement
RWS Holdings PLCTrading Statement
Travis Perkins PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
Whitbread PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Apr 2023 09:43

Avacta presents pre-clinical data for anti-cancer candidate

(Sharecast News) - Life science company Avacta Group announced the presentation of pre-clinical data for its novel 'preCISION' proteasome inhibitor AVA3996 on Monday.

Read more
6 Apr 2023 12:14

Avacta opens first two clinical investigator sites in US for AVA6000

(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application.

Read more
6 Apr 2023 10:09

Avacta opens first US clinical investigator sites

(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.

Read more
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.